TGA issues urgent warning on melanotan II tanning products

What just happened

The Therapeutic Goods Administration (TGA) has issued an urgent safety alert about melanotan II — a synthetic peptide marketed online as a tanning agent and circulating on social media under the nickname the “Barbie drug.” The alert follows enforcement action against a NSW individual for unlawfully supplying the substance.

Laboratory testing of seized products — nasal spray bottles labelled “Pure Tans Triple Strength 30 MG” — found that the actual melanotan II content ranged from 22 mg to 54 mg per bottle. The labelled dose was 30 mg. The real dose varied by more than twofold depending on the bottle.

Twenty-seven infringement notices totalling $101,412 were issued to a NSW individual for unlawful supply. The TGA’s advice is unambiguous: stop using these products.

That dosing variation is not a minor labelling technicality. Melanotan II is pharmacologically active — it has real physiological effects. When you cannot reliably know how much of a substance you are administering, safe use is not possible by definition.

Both-and

What melanotan II actually is

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), a peptide produced naturally in the body that regulates melanin synthesis and skin pigmentation. The synthetic version was initially investigated as a pharmaceutical candidate for certain skin conditions. It causes skin darkening by stimulating melanocytes — the cells that produce melanin.

No melanotan II product is listed on the Australian Register of Therapeutic Goods. It is not available from a pharmacy. Products circulate through online marketplaces and social media channels, often with branding that obscures the active ingredient — names like “Pure Tans,” “tanning peptide,” or “nasal tanner.”

The adverse effect profile is well-documented. Reported effects include nausea, vomiting, facial flushing, fatigue, and spontaneous erections in men. There are also effects on moles and pigmented lesions — clinically significant because any substance stimulating melanocyte activity can alter the appearance of naevi, and any change in a mole is a key early indicator in skin cancer assessment.

Cardiovascular and autonomic effects have also been reported. These are not obscure or theoretical adverse events; they are documented in the published pharmacology literature. This is not a supplement with a minor safety concern — it is a synthetic hormone analogue being self-administered via the postal system, with no dose verification and no medical supervision.

The social media pipeline

The “Barbie drug” nickname emerged from influencer content, where melanotan II is promoted alongside other unapproved aesthetic peptides — products marketed for muscle growth, fat loss, hair regrowth, sexual function, and anti-ageing. The framing is almost uniformly aspirational: effortless tan, no sun damage, no fake-tan upkeep. The adverse effects, the legal status, and the dose variability are rarely mentioned.

The TGA’s finding that a product in a specific branded line varied more than twofold in actual content depending on the individual bottle shows exactly what unregulated manufacture looks like in practice. The bottles looked identical. The doses were not.

This is part of a broader regulatory challenge. The unapproved peptide market is large, and enforcement action necessarily lags supply. This week’s TGA alert is enforcement-triggered — it followed seizure of specific products. It is not a warning that the supply of melanotan II has stopped.

The moles issue — a separate clinical flag

One point that deserves its own space: if you or someone you know has been using melanotan II and has noticed any change in a mole — size, shape, colour, border regularity, or the appearance of a new mole — that change warrants a GP assessment. It is not something to wait on.

Melanotan II’s mechanism of action directly and intentionally stimulates melanocytes. A substance that drives melanocyte activity carries a plausible pathway to affecting existing naevi. Clinicians should ask about use of unapproved tanning products when reviewing any new or changing skin lesion, particularly in the context of social media wellness products.

My two cents

This is a straightforward safety call. The TGA alert is unambiguous, the dosing finding is concrete, and the adverse effect profile is real.

What is worth naming is the broader frame this sits in. Melanotan II is not the same risk category as a poorly evidenced herbal supplement. It is a pharmacologically active synthetic hormone analogue. It has real effects on the body — that is the point — and the fact that it is being self-administered in unknown doses from unverified internet sources places any user in a genuinely uncontrolled situation.

The social media wellness economy has made this category of product feel routine. Peptide stacks, nasal sprays, subcutaneous injections delivered to your door — the branding is professional, the marketing is aspirational, and the regulatory status is not disclosed. The TGA’s enforcement action this week is a useful reminder of where this territory actually sits.

If you have been using melanotan II: stop, dispose of remaining product, and speak with your GP if you have experienced any adverse effects or if you have noticed any changes to moles or skin lesions. If a change in a mole has appeared during or after using any unapproved tanning product, that is a GP appointment worth making promptly.

Verdict: yes — stop using melanotan II products immediately. A GP conversation is warranted if you have experienced adverse effects or noticed any skin changes.

---

Sources cited

1. TGA issues urgent melanotan II tanning product warning. newsGP, RACGP, 18 August 2026. https://www1.racgp.org.au/newsgp/clinical/tga-issues-urgent-melanotan-ii-tanning-product-war
2. Australian Register of Therapeutic Goods. Therapeutic Goods Administration. https://www.tga.gov.au/how-we-regulate/australian-register-therapeutic-goods-artg